Canandaigua National Trust Co of Florida Acquires New Shares in Abbott Laboratories $ABT

Canandaigua National Trust Co of Florida acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,454 shares of the healthcare product maker’s stock, valued at approximately $1,033,000.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp grew its stake in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. J. Stern & Co. LLP increased its holdings in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Abbott Laboratories by 0.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock worth $2,241,076,000 after acquiring an additional 118,014 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Abbott Laboratories during the second quarter worth about $1,603,607,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.5%

NYSE ABT traded up $0.54 during mid-day trading on Wednesday, reaching $98.70. 9,392,108 shares of the stock were exchanged, compared to its average volume of 11,346,689. The stock has a market capitalization of $170.79 billion, a PE ratio of 31.94, a PEG ratio of 1.86 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $135.13. The business’s fifty day simple moving average is $106.71 and its 200 day simple moving average is $98.45.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.6%. Abbott Laboratories’s payout ratio is 81.55%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays initiated coverage with an “overweight” rating and a $120 price target, implying substantial upside from recent levels. The firm’s bullish view reflects growing confidence in Abbott’s medical-device and broader medtech exposure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
• Positive Sentiment: Analyst research highlighted a bullish initiation on Abbott, adding to favorable sentiment around the shares. This Abbott Analyst Begins Coverage On A Bullish Note
• Positive Sentiment: Evercore ISI raised its price target to $124 from $120 while maintaining an “outperform” rating, signaling confidence in Abbott’s longer-term earnings potential. Evercore ISI Adjusts Price Target on Abbott Laboratories
• Positive Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one product. The launch expands its consumer-health offering and targets growing mainstream wellness demand, though the near-term financial effect is likely limited. Abbott introduces Ensure Max Protein 3-in-1 Muscle Support
• Neutral Sentiment: Commentary describes ABT as a potential dividend bargain following its 2026 decline. Abbott has made 411 consecutive quarterly dividend payments since 1924, appealing to income-focused investors, but the company is not currently showing rapid growth trends. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
• Negative Sentiment: Abbott recently declined even as the broader market advanced, indicating continued stock-specific pressure and cautious investor sentiment. The pullback may improve dividend valuation, but it also reflects concerns about growth and near-term momentum. Abbott Stock Drops Despite Market Gains

Analysts Set New Price Targets

Several analysts have recently commented on ABT shares. Bank of America dropped their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their target price for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Barclays began coverage on Abbott Laboratories in a research report on Wednesday. They set an “overweight” rating and a $120.00 price target for the company. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.